retatrutide phase 2 trial Great news again!!! A of (Triple–Hormone-Receptor Agonist) for obesity. At 48 wks the median body weight loss was 24.2% and >5%, >10% and >15% had occurred in 100% Mazdutide vs retatrutide: dual agonist
Description
For the liraglutide group participants were started on: 2 metformin, 2 empagliflozin, 1 canagliflozin, 1 semaglutide
This extra receptor interaction enhances glucagon production, leading to the breakdown of stored fats and glycogen, thereby increasing basal metabolism for more consistent fat loss
This study highlights the importance of considering both the benefits and drawbacks of using GLP-1 agonists
This is called energy compensation
monitor lipid levels
